FDA Decision On Tolebrutinib MStranslate January 12, 2026 Clinical Trials Last week, we posted on Facebook that the FDA has decided to not approve tolebrutinib for the treatment of secondary progressive multiple sclerosis, despite positive Phase 3 trial results. In this article,...